Cantor Fitzgerald Estimates Atyr PHARMA FY2024 Earnings

Atyr PHARMA INC (NASDAQ:ATYR) – Research analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for Atyr PHARMA in a research report issued on Thursday, January 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings per share of ($0.91) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.89) per share.

Atyr PHARMA (NASDAQ:ATYR) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.01).

ATYR has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Wells Fargo & Company started coverage on shares of Atyr PHARMA in a research report on Friday, October 4th. They issued an “overweight” rating and a $17.00 price objective for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $19.25.

Atyr PHARMA Stock Performance

ATYR opened at $3.29 on Monday. The stock’s 50-day moving average is $3.37. Atyr PHARMA has a 52-week low of $1.39 and a 52-week high of $4.22. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $276.17 million, a price-to-earnings ratio of -3.50 and a beta of 1.08.

Hedge Funds Weigh In On Atyr PHARMA

A hedge fund recently raised its stake in Atyr PHARMA stock. JPMorgan Chase & Co. increased its stake in shares of Atyr PHARMA INC (NASDAQ:ATYR) by 52.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 31,440 shares of the company’s stock after buying an additional 10,754 shares during the period. JPMorgan Chase & Co.’s holdings in Atyr PHARMA were worth $55,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 61.72% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.